Monika Schöller-Gyüre **Tibotec BVBA** Generaal de Wittelaan LII B3 B2800. Mechelen Belgium mscholle@tibbe.jnj.com

# Pharmacokinetic evaluation of the interaction between TMCI25 and tenofovir disoproxil fumarate

M Schöller-Gyüre, C Debroye, B Woodfall, G De Smedt, F Aharchi, M Peeters, K Vandermeulen, R Hoetelmans

### Abstract

#### Background

TMC125 is an NNRTI with potent activity against both wild-type HIV and viruses resistant to currently approved NNRTIs. To support concomitant administration of the NtRTI tenofovir disoproxil fumarate (TDF) and TMC125, an interaction study was conducted with TDF and TMC125 (Phase III formulation) in HIV-negative volunteers.

#### Methods

TMC125-C177 was an open-label, two-period crossover, randomized trial. In Session I, 200mg TMC125 bid was administered for 7 days followed by a single morning dose on Day 8. After a washout period of 14 days, TDF 300mg qd was given from Day 1 to Day 16 of Session II. TMC125 200mg bid was coadministered during Days 9-15 in 12 volunteers randomized to Panel I and during Days 1-7 in 12 volunteers randomized to Panel 2 with a morning dose on Days 16 and 8, respectively. TMC125 and TDF were both administered after food intake. Plasma concentrations of TMC125 and tenofovir were assessed at steady-state over 12 and 24 hours, respectively. Pharmacokinetic (PK) parameters were estimated using noncompartmental methods and analyzed using a linear mixed effect model for a crossover design. Safety and tolerability were assessed. Results

### Twenty four male volunteers participated (median age 26 years). When combined with TDF, TMC125 AUC<sub>12b</sub> was 81% (90% CI: 75-88%) compared with administration of TMC125 alone. TMC125 C<sub>max</sub> and C<sub>min</sub> were 81% (90% CI: 75–88%) and 82% (90% CI: 73–91%), respectively. AUC<sub>24h</sub>, $C_{max}$ and $C_{min}$ of tenofovir were 115% (90% CI: 109-121%), 115% (90% CI: 104-127%) and 119% (90% CI: 113–126%), respectively, when combined with TMC125 compared with administration of TDF alone. Adverse events (AEs) were mild to moderate. The most common AEs were nasopharyngitis and headache (five subjects each). The concomitant administration of TMC125 and TDF was generally safe and well tolerated in this trial.

#### Conclusions


The changes in the pharmacokinetics of TMC125 or tenofovir when TMC125 is combined with TDF, are not clinically relevant. TMC125 and TDF can be coadministered without dose modifications.

#### Introduction

- TMC125 is a next generation NNRTI with potent in-vitro activity against h wild-type HIV-1 and HIV-1 resistant to current NNRTIs
- A Phase IIb trial (TMC125-C223) in treatment-experienced HIV patients nstrated that TMC125 with an optimized background regi reduced viral load at 48 weeks significantly more than active control. No dose-related effects on safety and tolerability were noted<sup>2,3</sup>
- TMC125 is predominantly metabolized by CYP3A4, CYP2C and
- TDF is an NtRTI, indicated for the treatment of HIV-infected adults
- Tenofovir is primarily eliminated via the kidney. In-vitro and in-vivo cted previously have demonstrated its limited drug-drug interaction potential
- To support the concomitant administration, an interaction study with TDF and TMC125 (Phase I formulation) was conduc

#### Study design

- TMC125-C177 was a Phase I, open-label, two-way, two-period crossove trial in which 24 HIV-negative volunteers were randomized to one of two panels as shown in the study design scheme . zed in a 1:1 ratio
- Two treatment sessions (I and I) were scheduled for all volunteers, separated by a washout period of at least 14 days. Within each panel, half the subjects were randomized to start with Session I and half were randomized to start with Session II
- All doses were taken within 10 minutes after a meal, the order of intake was TMC125, then TDF
- Post-treatment safety visits took place 7 days and 31 (±1) days after the last intake of trial medication
- The study protocol was reviewed and approved by the appropriate institutional ethics committee and health authorities, and was conducted in accordance with the Declaration of Helsinki




#### **Methods**

- Plasma concentrations of TMC125 were determined using a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method (LLOQ 2ng/mL)
- Plasma concentrations of tenofovir were determined using a validated HPLC method with fluorescence detection (LLOQ 20ng/mL)
- · PK and statistical PK analyses were performed using
- WinNonlin Professional<sup>™</sup> (version 4.1; Pharsight Corporation, Mountain View, CA, USA)
- Microsoft Excel® (version 2000; Microsoft, Redmond, WA, USA)
- SAS (version 9.1.3 SAS Institute Inc., Cary, NC, USA)
- · A non-compartmental model with extravascular input was used for the PK analysis

LLOQ = lower limit of quantification; HPLC = high performance liquid chromatograph

#### PK and safety parameters and statistical analyses

- Primary PK parameters
- C<sub>max</sub> (ng/mL): maximum plasma concentratio
- C<sub>min</sub> (ng/mL): minimum plasma concentration AUC 12h and AUC 24h (ng-h/mL): area under the plasma concentration time curve over 12 and 24-hour period, respectively, calculated by
- linear trapezoidal sur Safety parameters
- AEs, laboratory assessments, ECG, vital signs and physical examinations were evaluated throughout the study · Severity and drug relationship of AEs to TDF or TMC125 were
- Statistical analyses Descriptive statistics were calculated for the PK parameters of TMC125 and tenofovir
- Least square (LS) means were estimated with a linear mixed effects
- Safety parameters were evaluated by descriptive statistics and
  from upper tabulations frequency ta



6,040±1,557

695+144

338±114

0.81 (0.75-0.88)

0.81 (0.75\_0.88)

0.82 (0.73-0.91)

AUC<sub>12h</sub> (ng•h/mL) 7,638±2,254

876+233

426±155

C<sub>max</sub> (ng/mL)

C<sub>----</sub> (ng/mL)

SD = standard deviat



Tenofovir PK parameters (mean ± SD)			
PK parameter	TDF alone (reference) (n=19)	TDF + TMC125 (test) (n=19)	LS mean ratio (test/reference) (90% Cl)
AUC <sub>24h</sub> (ng•h/mL)	3,946±778	4,511±828	1.15 (1.09–1.21)
C <sub>max</sub> (ng/mL)	389±97	443±99	1.15 (1.04–1.27)
C <sub>min</sub> (ng/mL)	70±16	82±17	1.19 (1.13–1.26)
SD = standard deviation			
Safety summa	ary		

Poster No.

A-371

- No serious AEs or grade 3 or 4 AEs were reported • All reported AEs were mild in severity, except for one case of moderate hyperuricemia, not related to TMC125 or TDF
- The most frequent AEs were nasopharyngitis (six volunteers) and headache (five volunteers)
- · Four volunteers developed mild macular rash during TMC125 alone treatment and discontinued the study; all cases resolved without treatment within 10 days after discontinuation
- No consistent or relevant changes were found in laboratory or cardiovascular safety parameters, or physical examinations

## Conclusions

- When coadministered with TDF 300mg gd, TMC125 200mg bid exposure was decreased by 19% with similar decreases in  $C_{max}$  and  $C_{min}$ ; these effects are not clinically relevant.
- The 15% increase of tenofovir exposure after the coadministration of TDF 300mg qd with TMC125 200mg bid is not clinically relevant.
- Short-term coadministration of TMC125 with TDF in healthy volunteers was generally safe and well tolerated.
- TMC125 can be coadministered with TDF without dose adjustments.

## References

- Vingerhoets J, et al. J Virol 2005;79:12773-82.
- 2. Nadler I. et al. 10th European AIDS Conference 2005 (Poster LBPS3/7A).
- 3. Cohen C, et al. XVI International AIDS Conference 2006 (Poster TUPE0061).

# **Acknowledgments**

- The authors would like to acknowledge:
- M-P Bouche, J&J Pharmaceutical Research and Development, Beerse, Belgium
- Demeyer, Aalst Hospital Research Unit, Aalst, Belgium.